Ordinary Shares International Reporting
Verified Company Profile 6/16/2017
Contact Info
  • 700 Collip Circle,
  • Suite 114
  • London, ONT N6G 4X8
  • Canada

Business Description

Financial Reporting/Disclosure
Reporting Status International Reporting: TSX Venture Exchange
Audited Financials Audited
Latest Report Jul 31, 2017 Quarterly Report
CIK 0001491434
Fiscal Year End 10/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: Canada
Year of Inc. 1998
Employees 11 a/o Apr 30, 2017
Company Officers/Contacts
Philip M. Toleikis CEO
Scott Langille CFO
Company Directors
Frank Alfred Holler Chairman
Jeffrey Bacha
James Parsons
Philip M. Toleikis
Bruce Allen Weber
Service Providers
Accounting/Auditing Firm
Davidson & Company LLP
1200-609 Granville St
Suite 1200
Vancouver, BC, V7Y 1G6
Securities Counsel
McMillan LLP OTCQX Sponsor
Royal Centre, 1500-1055 West Georgia Street
PO Box 11117
Vancouver, BC, V6E 4N7
Investor Relations Firm
Ray Matthew & Associates
128 West Cordova Street
Suite 601
Vancouver, BC, V6B 0E8
Company History
  • Formerly=Pheromone Sciences Corp. until 3-07
SEOVF Security Details
Share Structure
Market Value1 $25,499,920 a/o Oct 20, 2017
Authorized Shares Unlimited a/o Apr 30, 2017
Outstanding Shares 159,374,498 a/o Apr 30, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 153,570,026 a/o Apr 30, 2017
Par Value No Par Value
Transfer Agent(s)
CST Trust Company
Shareholders of Record 1,262 a/o Apr 30, 2017
Non US Stock Exchange Listing
SVA - TSX Venture Exchange - Qualified
Short Selling Data
Short Interest 72 (-96.67%)
Sep 15, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security